Piekarska, Agnieszka and Abouqateb, Mouad and Boreland, William and Peczynski, Christophe and Zaucha, Jan Maciej and Kroger, Nicolaus and Zeiser, Robert and Ciceri, Fabio and Schroeder, Thomas and Luft, Thomas and Passweg, Jakob and Kunadt, Desiree and Stelljes, Matthias and Blau, Igor Wolfgang and Platzbecker, Uwe and Yakoub-Agha, Ibrahim and Blaise, Didier and Raiola, Anna Maria and Tischer, Johanna and Wagner-Drouet, Eva Maria and Winkler, Julia and Schmid, Christoph and Wulf, Gerald and Edinger, Matthias and Maertens, Johan and Stolzel, Friedrich and Vydra, Jan and Zak, Pavel and Moiseev, Ivan and Schoemans, Helene and Penack, Olaf and Peric, Zinaida (2025) Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors - an EBMT registry study by the Transplant Complications Working Party. BONE MARROW TRANSPLANTATION, 60 (12). pp. 1574-1583. ISSN 0268-3369, 1476-5365
Full text not available from this repository. (Request a copy)Abstract
The EBMT recommends rabbit anti-thymocyte or anti-T-lymphocyte globulin (rATG/ATLG) as GVHD prophylaxis in matched sibling donor (MSD) allogeneic hematopoietic cell transplantation (allo-HCT). However, discrepancies between recommendations and clinical practice were reflected in the EBMT survey. Therefore, we performed retrospective EBMT registry analysis from 2014 to 2021 to reinforce the real-world evidence context of rATG/ATLG impact on post-transplantation outcomes. This study included 11,420 adult patients (non-ATG n = 7680 and ATG n = 3740) with hematological malignancies after the first allo-HCT from peripheral blood. Use of ATG was associated with a reduced risk of aGVHD II-IV (Day +100: non-ATG vs ATG, 27.6% vs. 21.6%; adjusted HR 0.7, p < 0.001) and cGVHD (2-year: non-ATG vs ATG, 48.9% vs 30%; adjusted HR 0.45, p < 0.001), improved OS (2-year: 62.9% vs 63.3%; adjusted HR 0.89, p = 0.009), reduced NRM (2-year: 16% vs 12.5%; adjusted HR 0.63, p < 0.001), and higher GRFS (2-year: 32.2% vs 40.7%; adjusted HR 0.72, p < 0.001). While RI was higher in the ATG group (2-year: non-ATG vs ATG, 30.2% vs 34.7%; adjusted HR 1.22, p < 0.001) it did not translate into a significantly lower PFS (2-year: 53.9% vs 52.8%; adjusted HR not significant). Overall, outcomes were favorable for the intermediate rATG/ATLG dose ranges compared to the low and high dose ranges. Administration of rATG/ATLG improved outcomes in MSD allo-HCT recipients, supporting the EBMT recommendation for its use.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | VERSUS-HOST-DISEASE; STEM-CELL TRANSPLANTATION; ANTI-THYMOCYTE-GLOBULIN; HLA-IDENTICAL SIBLINGS; ACUTE MYELOID-LEUKEMIA; REGULATORY T-CELLS; ANTITHYMOCYTE GLOBULIN; HEMATOLOGICAL MALIGNANCIES; UNRELATED DONORS; ANTILYMPHOCYTE GLOBULIN; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 30 Mar 2026 09:10 |
| Last Modified: | 30 Mar 2026 09:10 |
| URI: | https://pred.uni-regensburg.de/id/eprint/67927 |
Actions (login required)
 |
View Item |
